fresolimumab
A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells.
| Synonym: | anti-TGF-beta monoclonal antibody GC1008 human anti-TGF-beta monoclonal antibody GC1008 |
|---|---|
| Code name: | GC1008 |
| Chemical structure: | immunoglobulin G4, anti-(human transforming growth factors beta-1, beta-2 (G-TSF or cetermin) and beta-3), human monoclonal GC-1008 γ4 heavy chain (134-215')-disulfide with human monoclonal GC-1008 κ light chain, dimer (226-226'':229-229'')-bisdisulfide immunoglobulin G4, anti-(transforming growth factor β) (human monoclonal GC-1008 heavy chain), disulfide with human monoclonal GC-1008 light chain, dimer |